Singapore markets close in 6 hours 11 minutes

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
47.69+0.54 (+1.15%)
At close: 04:00PM EDT
47.69 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close47.15
Open47.07
Bid47.68 x 200
Ask47.72 x 200
Day's range47.00 - 48.30
52-week range42.63 - 57.82
Volume1,662,994
Avg. volume1,949,198
Market cap119.056B
Beta (5Y monthly)0.45
PE ratio (TTM)20.83
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.04 (4.27%)
Ex-dividend date09 May 2024
1y target estN/A
All
News
  • GlobeNewswire

    Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

    Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITPRegulatory submissions in the US and EU anticipated by year-endRilzabrutinib is one of 12 potential medicines and vaccines in Sanofi’s robust immunology pipeline and a testament to Sanofi’s ability to successfully accele

  • GlobeNewswire

    Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

    New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS

  • GlobeNewswire

    Sanofi: Information concerning the total number of voting rights and shares - March 2024

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi